Literature DB >> 27866584

Lymphoma.

Emiliano N Mugnaini1, Nilanjan Ghosh2.   

Abstract

Lymphomas may be broadly divided into non-Hodgkin (90%) and Hodgkin (10%) types. Most lymphomas (90%) are of B cell origin but can also be T cell or natural killer cell. Clinical management of indolent and aggressive lymphomas is different. Aggressive lymphomas are more dangerous if left untreated yet a higher cell proliferation rate also renders them more chemosensitive, so they are managed with curative intent. Indolent lymphomas are, for the most part, incurable, such that quality of life must be balanced against toxicity of treatment in deciding when and how to treat.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Burkitt; Diffuse large B cell; Follicular; Hodgkin; Lymphoma; MALT; Non-Hodgkin; T cell

Mesh:

Substances:

Year:  2016        PMID: 27866584     DOI: 10.1016/j.pop.2016.07.012

Source DB:  PubMed          Journal:  Prim Care        ISSN: 0095-4543            Impact factor:   2.907


  23 in total

Review 1.  When Glycosylation Meets Blood Cells: A Glance of the Aberrant Glycosylation in Hematological Malignancies.

Authors:  Huining Su; Mimi Wang; Xingchen Pang; Feng Guan; Xiang Li; Ying Cheng
Journal:  Rev Physiol Biochem Pharmacol       Date:  2021       Impact factor: 5.545

2.  MicroRNA-383-5p predicts favorable prognosis and inhibits the progression of diffuse large B-cell lymphoma.

Authors:  Li-Yan Chen; Bi-Qing Han; Xiao-Min Zhang; Xing-Bao Yu; Dan-Dan Yao; Li-Qian Yu
Journal:  Oncol Lett       Date:  2021-05-06       Impact factor: 2.967

3.  Epstein-Barr Virus Infection of Cell Lines Derived from Diffuse Large B-Cell Lymphomas Alters MicroRNA Loading of the Ago2 Complex.

Authors:  Eckart Meese; Friedrich A Grässer; Hiresh Ayoubian; Nicole Ludwig; Tobias Fehlmann; Jennifer Menegatti; Laura Gröger; Eleni Anastasiadou; Pankaj Trivedi; Andreas Keller
Journal:  J Virol       Date:  2019-01-17       Impact factor: 5.103

4.  The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells.

Authors:  Benigno C Valdez; Yang Li; David Murray; Yan Liu; Yago Nieto; Richard E Champlin; Borje S Andersson
Journal:  Leuk Lymphoma       Date:  2017-04-10

Review 5.  Novel Effects of Statins on Cancer via Autophagy.

Authors:  Daniela Mengual; Luz Elena Medrano; Wendy Villamizar-Villamizar; Estefanie Osorio-Llanes; Evelyn Mendoza-Torres; Samir Bolívar
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-24

6.  Lymphoma cell-derived extracellular vesicles inhibit autophagy and apoptosis to promote lymphoma cell growth via the microRNA-106a/Beclin1 axis.

Authors:  Junling Tang; Peng Hu; Shixia Zhou; Tiejun Zhou; Xiaoming Li; Li Zhang
Journal:  Cell Cycle       Date:  2022-03-13       Impact factor: 5.173

Review 7.  Case study-based systematic review of literature on lymphoma-associated cardiac tamponade.

Authors:  Mohammad Abrar Shareef; Abdulaziz M Eshaq; Rasha Alshawaf; Emad Alharthi; Arwa A Al Muslat; Reema AbuDawas; Abdulhadi A AlAmodi
Journal:  Contemp Oncol (Pozn)       Date:  2021-02-23

8.  B-Cell Lymphoma in the Tricuspid Valve.

Authors:  Ali C Agha; Joseph Limback; Raul Loya; Ashley Ramirez; Michael Valente; Jeremy Burt
Journal:  Cureus       Date:  2016-12-16

9.  Effect of carboplatin injection on Bcl-2 protein expression and apoptosis induction in Raji cells.

Authors:  Peng Lin; Boliang Zhou; Haiying Yao; Ya-Ping Guo
Journal:  Eur J Histochem       Date:  2020-07-09       Impact factor: 3.188

10.  Systematic Analysis of Competing Endogenous RNA Networks in Diffuse Large B-Cell Lymphoma and Hodgkin's Lymphoma.

Authors:  Juanjuan Kang; Pengcheng Yao; Qiang Tang; Ying Wang; Yuwei Zhou; Jian Huang
Journal:  Front Genet       Date:  2020-09-30       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.